Sumitomo Dainippon Pharma Co Ltd (4506) - Financial and Strategic SWOT Analysis Review

Sumitomo Dainippon Pharma Co Ltd (4506) - Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH6665FSA
  • |
  • Pages: 63
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Sumitomo Dainippon Pharma Co Ltd (4506)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sumitomo Dainippon Pharma Co Ltd (Sumitomo Dainippon), a subsidiary of Sumitomo Chemical Co., Ltd, develops manufacturers, purchases, sells, imports and exports pharmaceutical products. The company focuses on major therapeutic areas which include central nervous system (CNS), cardiovascular, diabetes, oncology, respiratory psychiatry and neurology and infectious diseases. It also offers veterinary products, research materials, food additives, chemical product materials, food ingredients, diagnostic agents, cosmetic materials and other products. Sumitomo Dainippon has research laboratories, manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in the North America, Europe and Asia Pacific. Sumitomo Dainippon is headquartered in Chuo-ku, Osaka, Japan.

Sumitomo Dainippon Pharma Co Ltd Key Recent Developments

Jul 30,2018: Kyoto University Hospital and the Center for iPS Cell Research and Application (CiRA) to begin physician-initiated clinical trials for parkinson's disease

Jul 27,2018: Sumitomo Dainippon Pharma provides summary of consolidated financial results for the first quarter of the year ending March 31, 2019

Jul 17,2018: Sumitomo Dainippon Pharma Listed in FTSE4Good Index Series of Socially Responsible Investment and FTSE Blossom Japan Index

Jun 28,2018: Sumitomo Dainippon Pharma Contributes to Northern Osaka Earthquake Relief Efforts in Japan

Jun 15,2018: Sumitomo Dainippon Pharma Announces Management Changes

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Sumitomo Dainippon Pharma Co Ltd-Key Facts 6

Sumitomo Dainippon Pharma Co Ltd-Key Employees 7

Sumitomo Dainippon Pharma Co Ltd-Key Employee Biographies 9

Sumitomo Dainippon Pharma Co Ltd-Major Products and Services 10

Sumitomo Dainippon Pharma Co Ltd-History 12

Sumitomo Dainippon Pharma Co Ltd-Company Statement 20

Sumitomo Dainippon Pharma Co Ltd-Locations And Subsidiaries 21

Head Office 21

Other Locations & Subsidiaries 21

Section 2-Company Analysis 24

Company Overview 24

Sumitomo Dainippon Pharma Co Ltd-Business Description 25

Business Segment: Other 25

Overview 25

Performance 25

Business Segment: Pharmaceuticals 25

Overview 25

Performance 25

Geographical Segment: Japan 25

Performance 25

Geographical Segment: North America 26

Performance 26

Geographical Segment: Others 26

Performance 26

R&D Overview 26

Sumitomo Dainippon Pharma Co Ltd-Corporate Strategy 27

Sumitomo Dainippon Pharma Co Ltd-SWOT Analysis 28

SWOT Analysis-Overview 28

Sumitomo Dainippon Pharma Co Ltd-Strengths 28

Sumitomo Dainippon Pharma Co Ltd-Weaknesses 29

Sumitomo Dainippon Pharma Co Ltd-Opportunities 30

Sumitomo Dainippon Pharma Co Ltd-Threats 31

Sumitomo Dainippon Pharma Co Ltd-Key Competitors 32

Section 3-Company Financial Ratios 33

Financial Ratios-Capital Market Ratios 33

Financial Ratios-Annual Ratios 34

Performance Chart 37

Financial Performance 37

Financial Ratios-Interim Ratios 38

Financial Ratios-Ratio Charts 39

Section 4-Company's Lifesciences Financial Deals and Alliances 40

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 40

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 41

Sumitomo Dainippon Pharma Co Ltd, Recent Deals Summary 42

Section 5-Company's Recent Developments 43

Jul 30, 2018: Kyoto University Hospital and the Center for iPS Cell Research and Application (CiRA) to begin physician-initiated clinical trials for parkinson's disease 43

Jul 27, 2018: Sumitomo Dainippon Pharma provides summary of consolidated financial results for the first quarter of the year ending March 31, 2019 44

Jul 17, 2018: Sumitomo Dainippon Pharma Listed in FTSE4Good Index Series of Socially Responsible Investment and FTSE Blossom Japan Index 47

Jun 28, 2018: Sumitomo Dainippon Pharma Contributes to Northern Osaka Earthquake Relief Efforts in Japan 48

May 31, 2018: Sumitomo Dainippon Pharma Joins IFPMA as New Member[TOPC : Pharma-Sumitomo Dainippon Pharma Co Ltd] 49

May 11, 2018: Sumitomo Dainippon Pharma announces Changes in Board of Directors, Audit & Supervisory Board and Other Key Positions 50

May 11, 2018: Sumitomo Dainippon Pharma: Summary of Consolidated Financial Results for the Year Ended March 31, 2018 51

Apr 03, 2018: Sumitomo Dainippon Pharma Chooses Cytonome's GigaSort Cell Sorting Technology for Cell Bioprocessing 56

Mar 01, 2018: Sumitomo Dainippon Pharma Completes Manufacturing Plant for Regenerative Medicine & Cell Therapy 57

Mar 01, 2018: Sumitomo Dainippon Pharma Completes Manufacturing Plant for Regenerative Medicine & Cell Therapy 58

Section 6-Appendix 59

Methodology 59

Ratio Definitions 59

About GlobalData 63

Contact Us 63

Disclaimer 63

List of Figures

Sumitomo Dainippon Pharma Co Ltd, Performance Chart (2014-2018) 37

Sumitomo Dainippon Pharma Co Ltd, Ratio Charts 39

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 40

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 41

List of Tables

Sumitomo Dainippon Pharma Co Ltd, Key Facts 6

Sumitomo Dainippon Pharma Co Ltd, Key Employees 7

Sumitomo Dainippon Pharma Co Ltd, Key Employee Biographies 9

Sumitomo Dainippon Pharma Co Ltd, Major Products and Services 10

Sumitomo Dainippon Pharma Co Ltd, History 12

Sumitomo Dainippon Pharma Co Ltd, Other Locations 21

Sumitomo Dainippon Pharma Co Ltd, Subsidiaries 22

Sumitomo Dainippon Pharma Co Ltd, Key Competitors 32

Sumitomo Dainippon Pharma Co Ltd, Ratios based on current share price 33

Sumitomo Dainippon Pharma Co Ltd, Annual Ratios 34

Sumitomo Dainippon Pharma Co Ltd, Annual Ratios (Cont...1) 35

Sumitomo Dainippon Pharma Co Ltd, Annual Ratios (Cont...2) 36

Sumitomo Dainippon Pharma Co Ltd, Interim Ratios 38

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 40

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 41

Sumitomo Dainippon Pharma Co Ltd, Recent Deals Summary 42

Currency Codes 59

Capital Market Ratios 59

Equity Ratios 60

Profitability Ratios 60

Cost Ratios 61

Liquidity Ratios 61

Leverage Ratios 62

Efficiency Ratios 62

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Tsumura & co

Towa Pharmaceutical Co Ltd

Torii Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd

Shin-Etsu Chemical Co Ltd

Shin Nippon Biomedical Laboratories Ltd

Nippon Shinyaku Co Ltd

Mochida Pharmaceutical Co Ltd

Mitsubishi Tanabe Pharma Corp

Kissei Pharmaceutical Co Ltd

Chugai Pharmaceutical Co Ltd

Astellas Pharma Inc

Sumitomo Dainippon Pharma Co Ltd, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license
Single User License
USD 125 INR 8886
Site License
USD 250 INR 17773
Corporate User License
USD 375 INR 26659

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com